BR0012683A - Antagonistas bicìclicos seletivos para a integrina alfavbeta3 - Google Patents

Antagonistas bicìclicos seletivos para a integrina alfavbeta3

Info

Publication number
BR0012683A
BR0012683A BR0012683-7A BR0012683A BR0012683A BR 0012683 A BR0012683 A BR 0012683A BR 0012683 A BR0012683 A BR 0012683A BR 0012683 A BR0012683 A BR 0012683A
Authority
BR
Brazil
Prior art keywords
bicyclic
antagonists
selective
alpha
compounds
Prior art date
Application number
BR0012683-7A
Other languages
English (en)
Inventor
Arie Zask
Diane Barbara Hauze
Kenneth Lewis Kees
Richard Dale Coghlan
John Yardley
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of BR0012683A publication Critical patent/BR0012683A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"ANTAGONISTAS BICìCLICOS SELETIVOS PARA A INTEGRINA ALFA~ v~BETA~ 3~". Esta invenção fornece novos compostos bicíclicos da Fórmula (I): em que u, v, m, Y, G, A-B, R^ 1^, R^ 1a^, R^ 2^,R^ 4^,R^ 5^,R^ 5a^ e R^ 5b^ são definidos no relatório descritivo cujos compostos apresentam atividade como inibidores de reabsorção óssea e compostos da Fórmula (II) em que u, v, m, Y, G, D, A-B, R^ 1^, R^ 1a^, R^ 2^ , R^ 3^, R^ 4^, R^ 5^, R^ 5a^ e R^ 5b^ são definidos no relatório descritivo cujos compostos apresentam atividade como inibidores de reabsorção óssea.
BR0012683-7A 1999-07-21 2000-07-20 Antagonistas bicìclicos seletivos para a integrina alfavbeta3 BR0012683A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35803599A 1999-07-21 1999-07-21
PCT/US2000/019885 WO2001007036A1 (en) 1999-07-21 2000-07-20 BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN

Publications (1)

Publication Number Publication Date
BR0012683A true BR0012683A (pt) 2002-04-16

Family

ID=23408035

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012683-7A BR0012683A (pt) 1999-07-21 2000-07-20 Antagonistas bicìclicos seletivos para a integrina alfavbeta3

Country Status (9)

Country Link
US (1) US6429214B1 (pt)
EP (1) EP1198231A1 (pt)
JP (1) JP2003505416A (pt)
CN (1) CN1374863A (pt)
AU (1) AU6360200A (pt)
BR (1) BR0012683A (pt)
CA (1) CA2378860A1 (pt)
MX (1) MXPA02000722A (pt)
WO (1) WO2001007036A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
WO2003035618A2 (en) * 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
JP4566605B2 (ja) * 2004-04-02 2010-10-20 有限会社開発顧問室 短鎖ペプチドを有効成分とするコラーゲン合成阻害剤およびその製造方法
EP1812416B1 (en) * 2004-10-14 2013-08-21 Abbott GmbH & Co. KG Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
PT2123265E (pt) * 2008-05-23 2012-08-06 Novaera S R L Formulações de endipaleno no tratamento da psoríase
JP2014169243A (ja) * 2013-03-04 2014-09-18 Toray Fine Chemicals Co Ltd アミノアルコキシカルボスチリル誘導体の製造方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2621604A1 (de) 1976-05-14 1977-12-01 Bayer Ag Substituierte propan-1,3-diphosphonsaeuren und -phosphinsaeuren
DE2621605A1 (de) 1976-05-14 1977-12-01 Bayer Ag Organische derivate l-substituierter propan-1,3-diphosphonsaeuren und -phosphinsaeuren
DE2918160B2 (de) 1979-05-05 1981-05-27 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von 1.2-Diphosphonobernsteinsäureestern
DE2918162A1 (de) 1979-05-05 1980-11-20 Bayer Ag 1-halogenphosphonobernsteinsaeureester
US5312828A (en) 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
JPH0747582B2 (ja) 1989-12-11 1995-05-24 杏林製薬株式会社 キナゾリン―３―アルカン酸誘導体とその塩およびその製造法
PT100631B (pt) 1991-06-28 1999-06-30 Smithkline Beecham Corp Antagonistas biciclicos de fibrinogenio, seu uso e composicoes farmaceuticas que os contem
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
US5565449A (en) 1991-10-18 1996-10-15 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4208304A1 (de) * 1992-03-16 1993-09-23 Merck Patent Gmbh 2-oxochinolinderivate
US5473092A (en) 1992-11-20 1995-12-05 Monsanto Company Synthesis of optically-active phosphono analogs of succinates
JPH08511538A (ja) 1993-06-09 1996-12-03 スミスクライン・ビーチャム・コーポレイション 二環式フィブリノゲン拮抗物質
IL110172A (en) 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
US5731324A (en) 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US5683384A (en) 1993-11-08 1997-11-04 Zomed Multiple antenna ablation apparatus
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
CA2190870A1 (en) 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption
EP0777657A1 (en) 1994-08-22 1997-06-11 Smithkline Beecham Corporation Bicyclic compounds
US5629321A (en) 1994-10-27 1997-05-13 Mitsui Toatsu Chemicals, Inc. Bicyclic compound and platelet aggregation inhibitor containing the same
WO1996018602A1 (en) 1994-12-13 1996-06-20 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
WO1996026190A1 (en) 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
IL118325A0 (en) 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
PT910563E (pt) 1995-06-29 2003-09-30 Smithkline Beecham Corp Antagonistas de receptores de integrina
CZ40998A3 (cs) 1995-08-14 1998-09-16 The Scripps Research Institute Použití antagonisty anb5 pro výrobu prostředků, schopných inhibovat angiogenezi v tkáních
ATE203234T1 (de) 1995-08-30 2001-08-15 Searle & Co Meta-guanidine, harnstoff, thioharnstoff oder azacyklische aminobenzoesäure-derivate als integrin antagonisten
TW363051B (en) 1995-08-31 1999-07-01 Mitsui Toatsu Chemicals Substituted amidine derivatives and platelet aggregation inhibitor containing the same
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
CA2240439A1 (en) 1995-12-22 1997-07-03 The Dupont Merck Pharmaceutical Company Novel integrin receptor antagonists
KR19990076876A (ko) 1995-12-29 1999-10-25 스티븐 베네티아너 비트로넥틴 수용체 길항제
PL327694A1 (en) 1995-12-29 1998-12-21 Smithkline Beecham Corp Antagonists of vitronectin receptor
CN1209063A (zh) 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
JP2001527513A (ja) 1996-03-15 2001-12-25 デュポン ファーマシューティカルズ カンパニー スピロ環インテグリン阻害剤
PT796855E (pt) 1996-03-20 2002-07-31 Hoechst Ag Inibicao da reabsorcao nos ossos e antagonistas de vitronectina
JP2000506538A (ja) 1996-03-29 2000-05-30 ジー．ディー．サール アンド カンパニー メタ―置換フェニレン誘導体
JP2000508319A (ja) 1996-04-10 2000-07-04 メルク エンド カンパニー インコーポレーテッド αｖβ３拮抗薬
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
JP2001501951A (ja) 1996-10-07 2001-02-13 スミスクライン・ビーチャム・コーポレイション 骨形成刺激方法
US6130231A (en) 1996-11-27 2000-10-10 Dupont Pharmaceuticals Integrin receptor antagonists
CA2277273C (en) * 1997-01-17 2008-03-25 Merck & Co., Inc. Integrin antagonists

Also Published As

Publication number Publication date
JP2003505416A (ja) 2003-02-12
US6429214B1 (en) 2002-08-06
MXPA02000722A (es) 2002-07-22
EP1198231A1 (en) 2002-04-24
AU6360200A (en) 2001-02-13
CA2378860A1 (en) 2001-02-01
WO2001007036A1 (en) 2001-02-01
CN1374863A (zh) 2002-10-16

Similar Documents

Publication Publication Date Title
ATE225351T1 (de) Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel
IS6070A (is) Stofn af Bacillus Pumilus til stjórnunar á plöntusjúkdómum
BR0010220A (pt) Compostos de pirimidinona
DK1429802T3 (da) Tilførselssystem for biologisk komponent
CY1109413T1 (el) Μεθοδοι θεραπειας πολλαπλου μυελωματος και διεγειρομενης απο μυελωμα επαναρροφησης οστου χρησιμοποιωντας ανταγωνιστες συνδεσης ιντεγκρινης/υποδοχεα
DE60033025D1 (de) Knochenersatz aus kalziumphosphat
NO20006323L (no) Glykopeptid-derivater og farmasöytiske sammensetninger som inneholder disse
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
BR9815518A (pt) Agentes antibacterianos de oxazolidinona tendo funcionalidade de tiocarbonila
MY135333A (en) Modulators of the glucocorticoid receptor
BR0014384A (pt) Compostos para o tratamento da isquémia
ES2194223T3 (es) Antagonistas de la integrina.
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
NO993350L (no) Vitronectin-reseptor-antagonister
BR9704072A (pt) Derivados de cicloalquila como inibidores de ressorção de ossos e antagonistas de receptores vitronectina
DE69841198D1 (de) Klebstoffzusammensetzung für chirurgische Zwecke
AU5596298A (en) Integrin antagonists
PT1097127E (pt) Derivados de diacil-hidrazina como inibidores da integrina
ATE262519T1 (de) Heterozyklische ether- und thioether-verbindungen,verwendbar zur steuerung von chemischer synaptischer transmission
ECSP066605A (es) Derivados oxazol de tetraciclina
BR0215058A (pt) 2-fenil benzofuranos substituìdos como agentes estrogênicos
ES2195397T3 (es) Quinazolin-2,4-dionas sustituidas en posicion 7 utiles como agentes antibacterianos.
UA72948C2 (uk) Заміщені похідні фенілпіперазину, фармацевтична композиція та спосіб лікування афективних або неврологічних захворювань і розладів
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B25D Requested change of name of applicant approved